Non-Small Cell Lung Carcinoma – Page 2

AACR25: Boehringer touts new durability data for zongertinib in targeted lung cancer

6 months ago talkbio0Tagged AACR25, Boehringer, cellular targeting, durability, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Zongertinib

Malignant neoplasm of lung, AACR25, cellular targeting, Boehringer, Non-Small Cell Lung Carcinoma, Zongertinib, Zongertinib, durability

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

6 months ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics

Akeso, Summit’s PD-1/VEGF bispecific records another pivotal study win in NSCLC

6 months ago talkbio0Tagged Akeso, Combined, Ivonescimab, Keytruda, Non-Small Cell Lung Carcinoma, PD-1/VEGF, Pharmacotherapy, Safety, summit

Ivonescimab, Non-Small Cell Lung Carcinoma, Akeso, PD-1/VEGF, Keytruda, summit, Pharmacotherapy, Combined, Safety

Merck’s Injectable Keytruda Shows Promising Results in Pivotal Trial

7 months ago talkbio0Tagged Clinical Trials, intravenous formula, Keytruda, Non-Small Cell Lung Carcinoma, subcutaneous

Keytruda, subcutaneous injection, intravenous formula, non-small cell lung cancer, pivotal trial, Merck

J&J’s Subcutaneous Rybrevant Receives CHMP Backing for Lung Cancer Treatment Despite Recent FDA Rejection

9 months ago talkbio0Tagged amivantamab, CHMP, Epidermal Growth Factor Receptor, Johnson & Johnson, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, subcutaneous formulation, United States Food and Drug Administration

Rybrevant, amivantamab, Johnson & Johnson, CHMP, FDA, subcutaneous formulation, non-small cell lung cancer, EGFR mutations

J&J’s Rybrevant-Lazcluze Combo Demonstrates Superior Survival Benefit Over Tagrisso in EGFR-Mutated NSCLC

9 months ago talkbio0Tagged chemotherapy-free regimen, Epidermal Growth Factor Receptor, Lazcluze, Mutation, Non-Small Cell Lung Carcinoma, Overall Survival, Phase III MARIPOSA trial, Rybrevant, Tagrisso

Rybrevant, Lazcluze, Tagrisso, NSCLC, EGFR mutation, overall survival, Phase III MARIPOSA trial, chemotherapy-free regimen

J&J’s Rybrevant Combination Therapy Outperforms AstraZeneca’s Tagrisso in Lung Cancer Survival Trial

9 months ago talkbio0Tagged AstraZeneca, Combined Modality Therapy, J&J, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, Rybrevant, survival trial, Tagrisso

J&J, Rybrevant, AstraZeneca, Tagrisso, lung cancer, NSCLC, survival trial, combination therapy

AstraZeneca’s Tagrisso Expands EU Approval for NSCLC Treatment

10 months ago talkbio0Tagged Approved, AstraZeneca, Epidermal Growth Factor Receptor, EU, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Tagrisso

AstraZeneca, Tagrisso, NSCLC, EU approval, EGFR mutations, lung cancer treatment

FDA Approves Ensartinib for First-Line Treatment of ALK-Positive NSCLC

10 months ago talkbio0Tagged (ALK)-positive, Approved, ensartinib, Holdings, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, United States Food and Drug Administration, Xcovery

Ensartinib, ALK-positive NSCLC, FDA approval, lung cancer treatment, Xcovery Holdings

FDA Rejects Subcutaneous Version of J&J’s Lung Cancer Drug Rybrevant Due to Manufacturing Concerns

10 months ago talkbio0Tagged Epidermal Growth Factor Receptor, J&J, Malignant neoplasm of lung, manufacturing issues, Mutation, Non-Small Cell Lung Carcinoma, Rejection, Subcutaneous Rybrevant, United States Food and Drug Administration

FDA rejection, J&J, Subcutaneous Rybrevant, Manufacturing issues, Lung cancer drug, Non-small cell lung cancer (NSCLC), Epidermal growth factor receptor (EGFR) mutations